SLA Fondation (ALS Foundation France)

Number of service categories this organization offers.

• ✓1 service category listed

How broadly this organization advocates and informs the ALS community.

• —Raises ALS awareness
• —Online information source
• —Publishes research / reports
• —International reach
• —Engages in policy / advocacy

How easy it is for patients and families to reach this organization.

• ✓Has website
• —Has phone number
• ✓Has email
• ✓Has street address
• ✓Has map coordinates

Breadth of direct support offered to patients and families.

• —In-person support groups
• —Online support groups
• —Caregiver resources in services
• —Funds or provides home care
• —Children's resources

Percentage of profile fields with information.

• ✓Name
• ✓Type
• ✓Country
• ✓State / region
• ✓Address
• —Phone
• ✓Email
• ✓Website
• ✓Mission

Connections to research consortia and ALS networks.

• —Part of a consortia
• —International reach
• —Publishes research
• —Maintains an ALS database
• ✓Mentions a known network (NEALS, ENCALS, TRICALS, etc.)

Contact

Mission

US national research flagship; home of HEALEY ALS Platform Trial; NEALS Coordinating Center (CCC + DCC); Answer ALS partner. Lead: **Dr. Merit Cudkowicz, MD, MSc** — 2025 American Academy of Neurology lifetime achievement award recipient; Executive Director of Mass General Brigham Neuroscience Institute; HEALEY ALS Platform Trial principal investigator; NEALS co-founder (with Jeremy Shefner); one of the most-cited ALS researchers globally. HEALEY ALS Platform Trial — 1,300+ participants enrolled; 7 drugs evaluated; 2 advanced to Phase 3; 70+ trial sites nationwide First-ever platform trial design for ALS (modeled on I-SPY2 cancer precedent) Reduces average trial length by 50%; reduces cost by 30% Evergreen/perpetual design — adds new treatments continuously Regimens completed/active: Zilucoplan (UCB), Verdiperstat (Biohaven), CNM-Au8 (Clene Nanomedicine), Pridopidine (Prilenia, co-led by Shefner/Oskarsson), DNL343 (Denali Therapeutics), NUZ-001 (Neurizon Therapeutics, March 2026 launch), RAPA-501 (Expanded Access Protocol)